Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ACADBullishAnalyst Target Updateanalyst

Medium materiality6/10

RBC Raises Acadia Pharmaceuticals Price Target to $38

Nov 5, 2026, 1:27 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The target increase and sizable gap to the posted price are directionally positive, but the lack of a disclosed prior target limits how much weight to give the update.

AI summary

What happened, with direct paths to the underlying reporting

RBC Capital raised its ACAD price target to $38 from an unspecified prior level. The posted share price was $22.39, leaving substantial implied upside to the new target, though analyst targets are opinions.

RBC Capital raised its target to $38.
Posted price: $22.39; the prior target was not provided.

Key facts

01
Target: $38
02
Posted price: $22.39
03
Analyst firm: RBC Capital
04
Analyst: Brian Abrahams

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.